Vaxcyte’s stock has dropped around 45% despite a Phase II trial of its invasive pneumococcal disease (IPD) vaccine meeting ...

Vaxcyte, Inc.'s positive phase 2 results for VAX-24 show promise in preventing invasive pneumococcal disease in infants.

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning ...

Just as effective as the high dose, low-dose apixaban prevents long-term recurrent venous thromboembolism in patients with ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

For extended anticoagulation after venous thromboembolism (VTE) in patients with active cancer, a lower dose of apixaban ...

Claim construction hearing for Pfizer/BioNTech mRNA-LNP vaccine litigation occurred in December 2024; outcome pending Jury trial in Moderna U.S.

At the Tandem Meetings 2025, researchers presented a study of scalp cooling in patients undergoing chemotherapy and ASCT.

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

The original Pfizer vaccine was given in two doses scheduled three weeks apart. With the current updated formula, the vaccine is given as a single dose for anyone 5 years and older. For those who are ...

Arv­inas and Pfiz­er’s tar­get­ed pro­tein de­grad­er has not man­aged to dis­tin­guish it­self from oth­er, sim­i­lar breast can­cer drugs, ac­cord­ing to piv­otal da­ta re­ ...